Researchers at the University of Hong Kong have developed a world-first nasal spray that delivers neurotherapeutic powder directly to the brain as first aid for ischemic stroke patients. The treatment, named NanoPowder, is designed to reduce brain damage by more than 80 per cent and improve stroke survival rates. Clinical trials are expected by 2030.
Researchers at the University of Hong Kong (HKU) Li Ka Shing Faculty of Medicine and the university’s Advanced Biomedical Instrumentation Centre developed the medicine, known as NanoPowder. The nasal spray uses ‘nano-in-micron’ technology to bypass the blood-brain barrier, a natural shield that typically blocks most drugs from entering the brain, via the nose-to-brain pathway.
“We use ‘nano-in-micron’ technology to bypass the blood-brain barrier,” said Aviva Chow Shing-fung, a professor with the department of pharmacology and pharmacy who led the research team. “By using the nose-to-brain pathway, the treatment delivers medication directly to target areas, eliminating the need for surgery or injections.”
The treatment is intended for initial use by paramedics, before being rolled out to high-risk groups in care facilities and eventually the general public through pharmacies. The innovation won the Special Grand Prize and a gold medal at the 51st International Exhibition of Inventions Geneva this year.
